Key Market Indicators
Sales of antirheumatic medicine in New Zealand are on track to reach $5 million by 2026. In 2021, the country's sales of the medicine totaled $4.8 million, a decrease of around 0.5 percent annually since 1998. New Zealand placed 24th in the world rankings, with Luxembourg topping the list at $5 million. Germany, Spain, and Canada followed close behind, taking second, third, and fourth place, respectively.
